Abstract
The three β-adrenoceptor subtypes (β1, β2, β3) represent important therapeutic targets. The use of β2- adrenoceptor agonists as bronchodilators and β1 or β1/β2 antagonists as antihypertensives is well established; research is ongoing in these areas to refine pharmacodynamic properties. It is also feasible to design molecules combining β-adrenoceptor affinity with other pharmacophores. This is facilitated by the ability to confer β- adrenoceptor antagonist activity via attachment of a phenylethanolamine moiety or to incorporate diverse structural elements in the N-alkyl substituent of a β-adrenoceptor agonist or antagonist. β3-Adrenoceptor agonists have not yet been successfully developed as drugs for any therapeutic indication; nevertheless, during the past few years many highly potent and selective β3-agonists have been reported, some with good oral bioavailability. Selective β3-adrenoceptor antagonists have also been identified; useful pharmacological tools are now available for the evaluation of the functional role of each β-adrenoceptor subtype.
Keywords: Phenylethanolamine, phenoxypropanolamine, D2 receptor, phosphodiesterase, calcium channel
Current Topics in Medicinal Chemistry
Title: Recent Advances in Identification and Characterization of β-Adrenoceptor Agonists and Antagonists
Volume: 7 Issue: 2
Author(s): J. Paul Hieble
Affiliation:
Keywords: Phenylethanolamine, phenoxypropanolamine, D2 receptor, phosphodiesterase, calcium channel
Abstract: The three β-adrenoceptor subtypes (β1, β2, β3) represent important therapeutic targets. The use of β2- adrenoceptor agonists as bronchodilators and β1 or β1/β2 antagonists as antihypertensives is well established; research is ongoing in these areas to refine pharmacodynamic properties. It is also feasible to design molecules combining β-adrenoceptor affinity with other pharmacophores. This is facilitated by the ability to confer β- adrenoceptor antagonist activity via attachment of a phenylethanolamine moiety or to incorporate diverse structural elements in the N-alkyl substituent of a β-adrenoceptor agonist or antagonist. β3-Adrenoceptor agonists have not yet been successfully developed as drugs for any therapeutic indication; nevertheless, during the past few years many highly potent and selective β3-agonists have been reported, some with good oral bioavailability. Selective β3-adrenoceptor antagonists have also been identified; useful pharmacological tools are now available for the evaluation of the functional role of each β-adrenoceptor subtype.
Export Options
About this article
Cite this article as:
Hieble J. Paul, Recent Advances in Identification and Characterization of β-Adrenoceptor Agonists and Antagonists, Current Topics in Medicinal Chemistry 2007; 7 (2) . https://dx.doi.org/10.2174/156802607779318208
DOI https://dx.doi.org/10.2174/156802607779318208 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index To Volume 2
Current Cardiology Reviews Nocturia in Obstructive Sleep Apnea-Hypopnea Syndrome: An Underappreciated Symptom
Current Respiratory Medicine Reviews Update on COX-2 Selective Inhibitors: Chemical Classification, Side Effects and their Use in Cancers and Neuronal Diseases
Current Topics in Medicinal Chemistry Editorial [ Medicines Da Vinci Code: Deciphering the Intricate Origins of Clinical Neurovascular Pathology K. Maiese ]
Current Neurovascular Research Myricetin Induces Apoptosis in HepG2 Cells Through Akt/p70S6K/Bad Signaling and Mitochondrial Apoptotic Pathway
Anti-Cancer Agents in Medicinal Chemistry Recent Developments in Cardiovascular Drug Therapy: Treatment of Atrial Arrhythmias with New Class III Drugs and beyond
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Potential Application of Induced Pluripotent Stem Cells in Cell Replacement Therapy for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets SAR, Cardiac Myocytes Protection Activity and 3D-QSAR Studies of Salubrinal and its Potent Derivatives
Current Medicinal Chemistry Essential Fatty Acids - A Review
Current Pharmaceutical Biotechnology The Role of Adipocytokines and Neurohormonal Dysregulation in Metabolic Syndrome
Current Diabetes Reviews Non-Analgesic Effects of Opioids: Opioids and the Endocrine System
Current Pharmaceutical Design The DREAM of Pain Relief
Current Rheumatology Reviews An Overview of Piperazine Scaffold as Promising Nucleus for Different Therapeutic Targets
Current Pharmaceutical Design Heterocyclic Moieties as HDAC Inhibitors: Role in Cancer Therapeutics
Mini-Reviews in Medicinal Chemistry Renal Protective Effect of Metabolic Therapy in Patients with Coronary Artery Disease and Diabetes: From Bench to Bed Side
Current Pharmaceutical Design Evolving Concepts Concerning Cardiac β-Adrenoceptor Function in Heart Failure
Current Pharmaceutical Design Regulation of Cholesterol Biosynthesis and Absorption: Ultimate Management of Dyslipidemia with Statin and Ezetimibe
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Synergistic Effect of Inhibitors of MMPs and ROS-dependent Modifications of Contractile Proteins on Protection Hearts Subjected to Oxidative Stress
Current Pharmaceutical Design Male Pelvic Pain: Beyond Urology and Chronic Prostatitis
Current Rheumatology Reviews Immune-Mediated Mechanisms in Atherosclerosis: Prevention and Treatment of Clinical Manifestations
Current Pharmaceutical Design